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this study was to evaluate the cost-effectiveness of adding TVR to PR in treatment 
naive and previously treated patients with HCV in Argentina compared to PR alone 
and with the addition of BOC. Methods: A lifetime Markov model was developed 
including HCV, cirrhosis, liver transplant and death as health states. QALYs as an 
outcome measure, a private health subsector perspective and a 5% discount rate for 
health benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data was 
performed and when data were not available or validation was needed a Delphi 
panel with local experts was carried out. Deterministic and probabilistic sensitivity 
analysis was performed. Results: In comparison with PR, TVR avoided 166 cirrho-
sis cases and 13 deaths per 1,000 patients and shown an ICER of $141,922/QALY and 
$74,332/QALY for the naïve and for the previously treated patients respectively. TVR 
presented extended dominance (lower ICER) against BOC in naïve patients and com-
plete dominance (less costly and more efficacious) in most of the previously treated 
ones, except in the partial responders subgroup. Against the WHO criteria TVP ver-
sus PR presented a 42% of probability of being cost effective for naïve and 75% of 
probability of being cost effective for previously treated patients. ConClusions: 
TVR dominated BOC and its ICER against double therapy was slightly above WHO 
3x GDP criteria in Argentina from a private subsector perspective.
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objeCtivos: Evaluar la costo efectividad del uso de ácido gadotérico en reso-
nancia magnética para pacientes con insuficiencia renal crónica tipo 4 y 5, ver-
sus otros medios de contraste gadolínicos (gadopentetato de dimeglumina, 
gadoversetamida, gadodiamida, gadobutrol) analizando como desenlace la sobre-
vida del paciente que presenta como evento adverso Fibrosis Sistémica Nefrogénica 
(FSN). MetodologíAs: La efectividad de medios de contraste ha sido evaluada en 
términos de seguridad. Al revisar la literatura se encontraron diferencias en la proba-
bilidad de desarrollo (FSN) como principal complicación del uso de estos medios de 
contraste en pacientes con enfermedad renal avanzada, siendo letal en más del 56% 
de los casos. Mediante un modelo de árbol de decisión desde la perspectiva del tercero 
pagador se compararon los diferentes medios de contraste tomando como desenlace 
de análisis la sobrevida medida en años de vida ganados, para una esperanza de vida 
de 64,5 años y una edad promedio de 60 años, sobre las características del caso base. 
Los costos fueron obtenidos de precios de mercado de bases de datos de aseguradoras 
en pesos colombianos, 2012. El costo usado para las tecnologías fue el de la presen-
tación 15 ml. ResultAdos: No se encontraron reportes de casos de FSN con gado-
térico o gadobutrol. El ácido gadotérico mostró un promedio de año de vida de 1,706 
mejor que gadodiamida, gadopentetato de dimeglumina y gadoversetamida; y fue 
el menos costoso frente a todos los analizados (COP$ 132.000) seguido de Gadobutrol 
(COP$ 161.202) siendo dominante en todos los escenarios analizados. En el análisis 
tipo Montecarlo con variaciones de +/-50% mantiene su dominancia en el 95% de las 
iteraciones. ConClusiones: El acido gadotérico es la opción más favorable por su 
dominancia dada por su menor costo, y mejor o igual efectividad frente a los demás 
comparadores, justificando con esta información su mayor preferencia en el uso.
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objeCtives: The inflammatory bowel diseases (IBD) are characterized by chronic 
inflammation of the gastrointestinal tract; the irritable bowel syndrome (IBS) is a func-
tional disorder (prevalence 10%-20%). They present overlapping symptoms, making 
diagnosis difficult in primary care. Endoscopy is the gold standard for IBD, but it often 
turns negative due to IBD’s low prevalence, it is expensive, uncomfortable and risky 
for the patient. F-Calprotectin is a marker of intestine inflammation: as IBD patients 
exhibit levels higher than the general population and IBS patients, F-Calprotectin can 
be used to rule out IBD. The only CE evaluation on F-Calprotectin has been published 
by NHS (CEP09041, 2010); based on new evidence, we propose a refined model to evalu-
ate the CE of F-Calprotectin compared to the standard pre-endoscopic serologic test 
(CRP+ESR) to distinguish IBD from IBS in the UK and Brazil. Methods: F-Calprotectin 
sensitivity (0.96) and specificity (0.96) were evaluated from a meta-analysis performed 
in March 2013; CRP+ESR sensitivity (0.35) and specificity (0.73), and the costs come 
from CEP09041. Published HRQoL values for IBD and IBS were transformed in QALYs 
with transfer-to-utility techniques. The outcomes included cost savings, cost per 
QALY. Uncertainty was addressed with a probabilistic sensitivity analysis. Results: 
Results for UK show that F-Calprotectin is CE with respect to CRP+ESR: a) it results 
in more corrected IBD diagnoses at a lower price (it costs 113£ less per patient); b) it 
reduces the number of unnecessary endoscopies, increasing the number of correctly 
diagnosed IBD (N= 59) and IBS (N= 195) patients; c) it brings about a QALY gain per 
patient equal to 0.0034QALYs; the ICER of the CRP+ESR diagnostic strategy is 47,783£, 
and it falls well outside the cost-effectiveness bounds (20,000–30,000£ per additional 
QALY). Similar results were found for Brazil. ConClusions: F-Calprotectin is CE to 
rule out IBD in primary care in UK and Brazil.
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from 80.70% to 95.58% while that of control was 88.56%. Therapeutic complications 
knowledge was increased from 71.58% to 88.57% while that of control was 78.82%. 
Medication knowledge of diabetes was increased from 80.26% to 83.67% while that 
of control was 74.51%. Lifestyle knowledge of diabetes was increased from 72.81% to 
89.80% while that of control was 84.64%. Knowledge about preventions in diabetes 
was increased from 69.47% to 86.53% while that of control was 80.78%. Knowledge 
about diet was increased from 48.68% to 77.55% while that of control was 42.16%. 
Knowledge about monitoring diabetic conditions was increased from 84.21% to 
92.35% while that of control was 86.27. Scores in all diabetic knowledge aspect 
was increased after education intervention and was significantly (P< 0.05) different 
from that of control group. ConClusions: Institutions may ethically help in the 
reinforcement of student’s knowledge by implementing such educational programs 
which may increase the educational skills, efficiency and confidence of pharmacy 
students as well as professionals.
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objeCtives: To investigate the effects of BPA on oxidative damage in terms of activ-
ity level of antioxidant enzymes in different regions of the rat brain. Methods: 
In this study, BPA migration was estimated through physio-chemical parameters 
and leachate (equivalent to 4mg/kg body weight) was used for animal dosing. 
Three groups of Albino Wister rats (190+20grm) were used for control, sham, and 
treated. The antioxidant enzymes including superoxide dismutase (Mn-SOD), cata-
lase (CAT), glutathione peroxidase (GPx) and reduced glutathione level (GSH) were 
measured in different brain regions i.e. corpus striatum, frontal cortex, thalamus 
and midbrain. Results: No significant changes were observed in most of the 
brain regions yet the level of GPx activity in corpus striatum (29.65±0.98 nmoles/
min/mg protein) and level of GSH activity in frontal cortex (2.33±0.12 µmoles/g 
protein) was found to decrease significantly (p< 0.05) when compared to controls. 
In addition, no significant effects were observed for the oxidative damage in brain 
regions of sham group when compared to control group. ConClusions: Thus 
study suggests that acute exposure (4mg/kg body weight per day up to 28 days) of 
BPA does not induce significant oxidative damage in the rat brain. Furthermore, 
study might re-examine before affirm the final remark for subscribers and regula-
tory bodies at similar doses.
GAstroIntestInAl DIsorDers – Clinical outcomes studies
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objeCtives: To estimate the cost of treatment of primary biliary cirrhosis with 
ursodeoxycholic acid (UDCA) in Brazil and to evaluate the efficacy and safety of 
this treatment. Methods: We considered the doses of 8, 12 and 15mg/Kg and 
a patient weighing 70Kg to estimate the cost of treatment. We used the maxi-
mum price to the producer in the CMED (Drug Market Regulation Chamber) list 
of 03/15/2013 with 18% of ICMS (Circulating Goods and Services Tax), and applied 
CAP (Adequacy Coefficient of Prices)of 25% . We used Purchasing Power Parity 
of 1,0USD= 1,8BRL. To access efficacy and safety we searched the databases The 
Cochrane Library, CDR, Tripdatabase, MEDLINE and LILACS to identify systematic 
reviews (SR) of clinical trials that reported data on mortality, biochemical improve-
ment measurements and adverse events. Results: The estimated annual cost of 
treatment was USD2,239.24 with the dose of 8mg/Kg; USD3,168.97with the dose 
of 12mg/Kg; and UDS4,098.71 with the dose of 15mg/Kg. We included seven SRs; 
four evaluating UDCA versus placebo/observation; one UDCA versus colchicine; 
one UDCA versus methotrexate; and one UDCA versus bezafibrate. Generally, until 
four years of treatment there were no difference between UDCA and placebo/other 
interventions with respect with mortality, hepatic transplant incidence, wors-
ening or arising of itching and fatigue, and incidence of hepatic complications. 
In the other hand there were improvements in surrogate outcomes like hepatic 
function markers, especially bilirubin. In all studies UDCA was well tolerated by 
patients. ConClusions: Improvements in the blood levels of hepatic markers 
did not match mortality rates or the incidence of transplant. The main symptoms 
of the disease, itching or fatigue, were not altered by the use of UDCA. There is a 
lack of evidence of studies evaluating quality of life of the patients, which perhaps 
could be improved by the use of UDCA. Besides, long observational studies could 
connect biochemical improvement and mortality rate.
GAstroIntestInAl DIsorDers – Cost studies
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objeCtives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV (PR) 
are a new therapeutic option with higher rates of sustained virological response 
(SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, two alternatives 
of DAA, telaprevir (TVR) and boceprevir (BOC), are available in Argentina. The aim of 
